Free Cash Flow CAGR:66.82%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, Free Cash Flow CAGR averages 3.40% over 3 years and 8.74% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how the company's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
EW Free Cash Flow CAGR Chart
Edwards Lifesciences Corporation (EW)
EW Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
EW Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $289.90M | $1.33B | +$1.05B | +360.50% | +360.50% |
| 2024 | $629.50M | $289.90M | $-339.60M | -53.95% | -53.95% |
| 2023 | $953.40M | $629.50M | $-323.90M | -33.97% | -33.97% |
| 2022 | $1.40B | $953.40M | $-448.90M | -32.01% | -32.01% |
| 2021 | $647.00M | $1.40B | +$755.30M | +116.74% | +116.74% |
| 2020 | $901.00M | $647.00M | $-254.00M | -28.19% | -28.19% |
| 2019 | $685.10M | $901.00M | +$215.90M | +31.51% | +31.51% |
| 2018 | $825.20M | $685.10M | $-140.10M | -16.98% | -16.98% |
| 2017 | $487.00M | $825.20M | +$338.20M | +69.45% | +69.45% |
| 2016 | $443.20M | $487.00M | +$43.80M | +9.88% | +9.88% |
| 2015 | $928.60M | $443.20M | $-485.40M | -52.27% | -52.27% |
| 2014 | $362.60M | $928.60M | +$566.00M | +156.09% | +156.09% |
| 2013 | $246.10M | $362.60M | +$116.50M | +47.34% | +47.34% |
| 2012 | $223.90M | $246.10M | +$22.20M | +9.92% | +9.92% |
| 2011 | $188.40M | $223.90M | +$35.50M | +18.84% | +18.84% |
| 2010 | $101.30M | $188.40M | +$87.10M | +85.98% | +85.98% |
| 2009 | $75.20M | $101.30M | +$26.10M | +34.71% | +34.71% |
| 2008 | $147.70M | $75.20M | $-72.50M | -49.09% | -49.09% |
| 2007 | $171.40M | $147.70M | $-23.70M | -13.83% | -13.83% |
| 2006 | $88.30M | $171.40M | +$83.10M | +94.11% | +94.11% |
| 2005 | $138.10M | $88.30M | $-49.80M | -36.06% | -36.06% |
| 2004 | $84.40M | $138.10M | +$53.70M | +63.63% | +63.63% |
| 2003 | $79.90M | $84.40M | +$4.50M | +5.63% | +5.63% |
| 2002 | $63.00M | $79.90M | +$16.90M | +26.83% | +26.83% |
| 2001 | $91.00M | $63.00M | $-28.00M | -30.77% | -30.77% |
| 2000 | $134.00M | $91.00M | $-43.00M | -32.09% | -32.09% |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | -$21.10M | — | — |
| Q4 2025 | $353.50M | -31.5% | — |
| Q3 2025 | $516.20M | +114.3% | +61.4% |
| Q2 2025 | $240.90M | +7.4% | -15.8% |
| Q1 2025 | $224.40M | — | — |
| Q4 2024 | -$177.30M | — | — |
| Q3 2024 | $319.90M | +11.8% | -10.2% |
| Q2 2024 | $286.10M | — | — |
| Q1 2024 | -$138.80M | — | — |
| Q4 2023 | $35.00M | -90.2% | -81.9% |
| Q3 2023 | $356.20M | — | +42.5% |
| Q2 2023 | -$14.30M | — | — |
| Q1 2023 | $252.60M | +30.4% | +14.5% |
| Q4 2022 | $193.70M | -22.5% | -30.8% |
| Q3 2022 | $250.00M | -13.5% | -46.9% |
| Q2 2022 | $289.10M | +31.1% | -36.7% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian